CL2017002920A1 - Régimen modulador selectivo de los receptores de progesterona (sprm). - Google Patents

Régimen modulador selectivo de los receptores de progesterona (sprm).

Info

Publication number
CL2017002920A1
CL2017002920A1 CL2017002920A CL2017002920A CL2017002920A1 CL 2017002920 A1 CL2017002920 A1 CL 2017002920A1 CL 2017002920 A CL2017002920 A CL 2017002920A CL 2017002920 A CL2017002920 A CL 2017002920A CL 2017002920 A1 CL2017002920 A1 CL 2017002920A1
Authority
CL
Chile
Prior art keywords
uterine
fibromioms
sprm
regimen
progesterone receptors
Prior art date
Application number
CL2017002920A
Other languages
English (en)
Inventor
Christian Seitz Dr
Rudolf Knauthe Dr
Susan Zeun Dra
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53180494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002920(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2017002920A1 publication Critical patent/CL2017002920A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA INVENCIÓN ESTÁ DESTINADA A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN ANTAGONISTA RECEPTOR DE PROGESTERONA LLAMADO (11ß,17ß)-17-HIDROXI-11-[4-(METILSULFONIL)FENIL]-17-(PENTAFLUOROETIL)ESTRA-4,9-DIEN-3-ONA PARA EL TRATAMIENTO Y/O LA PROFILAXIS DE FIBROMIOMAS UTERINOS (MIOMAS, LEIOMIOMA UTERINO) QUE SE ADMINISTRA DIARIAMENTE A UN PACIENTE DIAGNOSTICADO CON FIBROMIOMAS UTERINOS MEDIANTE EL SEGUIMIENTO DE UN RÉGIMEN ESPECÍFICO. ADEMÁS, LA INVENCIÓN ESTÁ DIRIGIDA A UN MÉTODO PARA EL TRATAMIENTO CONTRA LOS FIBROMIOMAS UTERINOS (MIOMAS, LEIOMIOMA UTERINO) Y/O PARA LA REDUCCIÓN DEL TAMAÑO Y LOS SÍNTOMAS DE LOS FIBROMIOMAS UTERINOS (MIOMAS, LEIOMIOMA UTERINO) MEDIANTE EL SEGUIMIENTO DE UN RÉGIMEN ESPECÍFICO AL IGUAL QUE UN TRATAMIENTO CONTRA EL SANGRADO MENSTRUAL ABUNDANTE (HMB).</p>
CL2017002920A 2015-05-18 2017-11-17 Régimen modulador selectivo de los receptores de progesterona (sprm). CL2017002920A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001475 2015-05-18

Publications (1)

Publication Number Publication Date
CL2017002920A1 true CL2017002920A1 (es) 2018-05-18

Family

ID=53180494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002920A CL2017002920A1 (es) 2015-05-18 2017-11-17 Régimen modulador selectivo de los receptores de progesterona (sprm).

Country Status (19)

Country Link
US (3) US20180155388A1 (es)
EP (2) EP3417863A1 (es)
JP (2) JP2018515551A (es)
KR (1) KR20180004814A (es)
CN (2) CN113797210A (es)
AU (1) AU2016262826A1 (es)
BR (1) BR112017024627A2 (es)
CA (1) CA2986064A1 (es)
CL (1) CL2017002920A1 (es)
EA (2) EA035567B1 (es)
HK (1) HK1245118A1 (es)
IL (1) IL255451A0 (es)
MA (2) MA46298A (es)
MX (1) MX2017014844A (es)
PH (1) PH12017502100A1 (es)
SG (1) SG10201910441PA (es)
TN (1) TN2017000482A1 (es)
TW (1) TW201707708A (es)
WO (1) WO2016184863A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46298A (fr) * 2015-05-18 2019-07-31 Bayer Pharma AG Modulateur sélectif du récepteur de la progestérone (sprm) pour son utilisation dans le traitement des saignements menstruels abondants
EP3214092A1 (en) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient
WO2019080811A1 (zh) * 2017-10-26 2019-05-02 苏州科睿思制药有限公司 一种选择性孕酮受体调节剂的晶型及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
JP2001520820A (ja) * 1997-02-03 2001-10-30 エムシーアイ・ワールドコム・インコーポレーテッド 通信システム構造
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
CA2524474A1 (en) 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
ES2391334T3 (es) 2005-06-21 2012-11-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la IL-1beta
PT2272272T (pt) 2008-04-30 2016-07-15 ERICSSON TELEFON AB L M (publ) Utilização da própria ligação de rádio como uma ligação de transporte para algumas das estações base em lte
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
US9643993B2 (en) * 2012-09-28 2017-05-09 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
EP2914268B1 (en) * 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
KR20140077499A (ko) * 2012-12-14 2014-06-24 에스케이하이닉스 주식회사 저항 변화 메모리 장치 및 그 제조방법
UY35528A (es) * 2013-04-10 2014-09-30 Preglem Sa Moduladores del receptor de la progesterona para uso en la terapia de fibromas uterinos
PT2983671T (pt) * 2013-04-11 2019-02-25 Bayer Pharma AG Forma farmacêutica de antagonista de recetor de progesterona
MA46298A (fr) 2015-05-18 2019-07-31 Bayer Pharma AG Modulateur sélectif du récepteur de la progestérone (sprm) pour son utilisation dans le traitement des saignements menstruels abondants
EP3384913A1 (en) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient

Also Published As

Publication number Publication date
EA036237B1 (ru) 2020-10-16
CA2986064A1 (en) 2016-11-24
MA42103A (fr) 2018-03-28
CN107635562A (zh) 2018-01-26
WO2016184863A1 (en) 2016-11-24
TW201707708A (zh) 2017-03-01
EA035567B1 (ru) 2020-07-08
EP3417863A1 (en) 2018-12-26
US20190375783A1 (en) 2019-12-12
EA201792524A1 (ru) 2018-04-30
IL255451A0 (en) 2017-12-31
MX2017014844A (es) 2018-02-19
JP2018515551A (ja) 2018-06-14
MA46298A (fr) 2019-07-31
US20190211053A1 (en) 2019-07-11
TN2017000482A1 (en) 2019-04-12
PH12017502100A1 (en) 2018-05-07
JP2021098702A (ja) 2021-07-01
BR112017024627A2 (pt) 2018-07-31
EA201990106A1 (ru) 2019-05-31
AU2016262826A1 (en) 2017-11-30
SG10201910441PA (en) 2020-01-30
KR20180004814A (ko) 2018-01-12
HK1245118A1 (zh) 2018-08-24
US10858388B2 (en) 2020-12-08
US20180155388A1 (en) 2018-06-07
EP3297635A1 (en) 2018-03-28
CN113797210A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
MX385194B (es) Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2019000571A1 (es) Formulaciones de carbamato de (r) -2-amino-3-fenilpropilo.
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
CL2017002920A1 (es) Régimen modulador selectivo de los receptores de progesterona (sprm).
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MY210254A (en) Selective estrogen receptor degraders
PH12014502331B1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
CL2017002017A1 (es) Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico
CL2017001479A1 (es) Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
MX391949B (es) Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
AR089114A1 (es) PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion &#34;a la carta&#34;.
ECSP12012331A (es) Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
AR095638A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario
CL2015003434A1 (es) Composición farmacéutica, su uso y régimen de administración para contracepción a demanda.